© Reuters. Mylan stock boost follows long share struggles for company, generics industry By Lewis Krauskopf NEW YORK (Reuters) – Shares of Mylan NV (O:) surged on Monday after the generic drugmaker agreed to combine with Pfizer Inc’s (N:) off-patent branded drugs business. But in the bigger picture, the surgeRead More →
© Reuters. FILE PHOTO: Mylan CEO Heather Bresch holds EpiPens during a House Oversight and Government Reform Committee hearing on the Rising Price of EpiPens at the Capitol in Washington By Michael Erman and Ankur Banerjee (Reuters) – Pfizer Inc (N:) has agreed to spin off its off-patent branded drugsRead More →
ZURICH (Reuters) – Novartis (S:) Chief Executive Vas Narasimhan pledged in an interview published on Saturday not to sell the Swiss drugmaker’s generics unit Sandoz amid a revamp that has prompted speculation he is preparing to offload the business. “No, we will not sell Sandoz,” Narasimhan told the Sueddeutsche ZeitungRead More →
